- All study subjects have been dosed in the initial Phase I programme with product candidate TB-403 for treatment of cancer.

 - Two drug interaction studies are ongoing and proceed as planned with the drug TB-402 for the prevention of blood clots. Results from these studies are expected to be available during the second quarter.
        
 - The Phase I programme with product candidate BI-204 for treatment of atherosclerosis proceeds as planned.

- Entered into an agreement with Bayer HealthCare for research and development of antibody-based drugs.

- Net revenues for January - March 2008: SEK 16.2 million (118.0 including initial partial payment of SEK 105.5 for BI-204).

- Cash flow from current operations and investment activities for January - March 2008: SEK -59.2 million (85.7).

- Current investments together with cash and bank as of 31 March 2008: SEK 157.7 million (173.7).

- Loss after tax for January - March 2008 amounted to SEK -39.9 million (72.7) and the profit after tax per share was SEK -0.72 (1.54).